Serum fibroblast growth factor 19 is decreased in patients with overt hypothyroidism and subclinical hypothyroidism.
As a newly emerging metabolic regulator, accumulating evidence suggests that the circulating fibroblast growth factor 19 (FGF19) level correlated with lipid and glucose metabolism. Several independent groups have found that FGF19 was highly likely associated with multiple metabolic disorders. Thyroid dysfunction is believed to be associated with metabolism diseases. However, to date, few studies have investigated the role of FGF19 in patients with thyroid dysfunctions. For this purpose, a cross-sectional study was done to estimate the role of FGF19 in patients with different thyroid functions. Compared with the healthy control, the present study revealed that serum FGF19 levels were significantly decreased in overt hypothyroidism patients (78.7 [52.7-121.2] vs 292.4 [210.2-426.5] pg/mL, P <0.001). FGF19 concentration was also lower in the subclinical hypothyroidism group than it was in the healthy control group (95.8 [71.7-126.3] vs 292.4 [210.2-426.5] pg/mL, P <0.001). However, there was no significant difference in FGF19 level between the isolated thyroid autoantibody positive group and the healthy control group (252.0 [205.9-353.5] vs 292.4 [210.2-426.5] pg/mL, P >0.05). Also, serum thyroid stimulating hormone (TSH) was an independent predictor of FGF19. In conclusion, thyroid insufficiency but not thyroid autoimmunity may have impacted serum FGF19 concentrations. As the role of FGF19 is becoming more and more important in the pathogenesis of many metabolic diseases, we proposed that the thyroid hormone level should be taken into account when the serum concentration is explained. Further studies are needed to elucidate the role of FGF19 in the development of hypothyroidism.
The Liaoning Provincial Key Laboratory of Endocrine Disease, Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, China Medical University, Shenyang, China.
Yaxin
Y
Lai
Haoyu
H
Wang
Xinghai
X
Xia
Zhaojun
Z
Wang
Chenling
C
Fan
Hong
H
Wang
Hongmei
H
Zhang
Shuangning
S
Ding
Weiping
W
Teng
Zhongyan
Z
Shan
D015415:Biomarkers / Q000097:blood; D003430:Cross-Sectional Studies; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood*; D005500:Follow-Up Studies; D006801:Humans; D007037:Hypothyroidism / Q000097:blood* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013960:Thyroid Function Tests
D015415:Biomarkers; C117476:FGF19 protein, human; D005346:Fibroblast Growth Factors
PLoS One. 2013 Jun 26;8(6):e67160
23840612
Sci Rep. 2016 Jun 27;6:28431
27345212
PLoS One. 2014 Oct 14;9(10):e109549
25313993
Clin Endocrinol (Oxf). 2011 Jul;75(1):1-9
21521298
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16109-14
24043787
J Clin Endocrinol Metab. 2015 Apr;100(4):1630-8
25629356
Eur J Clin Invest. 2011 Feb;41(2):159-66
21039443
Thyroid. 2012 May;22(5):454-60
22510014
Endocr J. 2013;60(8):977-83
23759753
Thyroid. 2008 Aug;18(8):825-30
18651824
Cell. 2013 May 9;153(4):747-58
23623304
Biomed Res Int. 2016;2016:5090852
27213151
Nat Rev Drug Discov. 2013 Jul;12(7):504
23787955
Lipids Health Dis. 2012 Jan 30;11:17
22289392
Biomed Res Int. 2014;2014:963230
25003133
PLoS One. 2013 Aug 07;8(8):e72345
23940810
Biomed Res Int. 2015;2015:351831
26273610
PLoS One. 2015 Aug 13;10(8):e0135233
26270348
PLoS One. 2013 Nov 19;8(11):e81190
24260557
Biochem Biophys Res Commun. 2014 Jan 10;443(2):477-82
24321096
Eur Thyroid J. 2013 Jun;2(2):83-92
24783045
Biol Pharm Bull. 2014;37(7):1081-9
24988999
Endocrinology. 2002 May;143(5):1741-7
11956156
Endocrinology. 2004 Jun;145(6):2594-603
14976145
Endocr J. 2011;58(1):23-30
21135510
J Hepatol. 2014 Dec;61(6):1358-64
25016220
Expert Opin Investig Drugs. 2015 May;24(5):603-10
25604607